Solta Medical, Inc. , leader in medical devices for aesthetic treatment recently announced an exclusive partnership with SkinCeuticals, a provider of professional skincare technology, to provide first fractional laser treatment as well as antioxidant skincare regimen for office and home use.
The partnership will combine data from clinical research undertaken by Solta and SkinCeuticals. The research analyzed the merits of using Clear+Brilliant Laser System along with its handpiece Permea, manufactured by Solta and SkinCeutical’s antioxidant named CE Ferulic.
The results from the clinical research indicate enhanced patient satisfaction based on the appearance of the skin. Skin treatment using Clear+Brilliant Permea followed by CE Ferulic resulted in a reduced post-treatment recovery time. As per statistics, the combination of CE Ferulic and Clear+Brilliant Laser System can lower the recovery time by two days. The patients also experienced less redness and swelling.
Management at Solta is enthused about its partnership with SkinCeuticals. The company considers its Clear+Brilliant system to be the preferred choice for physicians who want to offer maximum benefits of a fractional resurfacing treatment to their patients. The addition of the Permea handpiece and inclusion of CE Ferulic in the treatment regimen will allow Solta to offer holistic treatment to patients in the office as well as at home.
According to management at SkinCeuticals, laser treatment offered by Solta complements its skincare technology. CE Ferulic offers antioxidant treatment to negate the harmful free radicals and enhance the skin’s natural photoprotection eight times. It can also curtail inflammation and activate collagen synthesis.
Solta is a developer and manufacturer of medical devices for aesthetic application for physician-led, professional assists and personal care market. The company operates in a burgeoning market, given the demand outlook and demographic trend. Its partnership with SkinCeuticals underlines Solta’s commitment towards the aesthetic medical industry. The company has a history of product innovation and successful takeovers to boost its top-line.
However, the market that Solta serves is susceptible to macroeconomic pressure. Moreover, the company faces tough competition from Syneron Medical Ltd. (ELOS - Snapshot Report).
Solta currently retains a Zacks #3 Rank, which translates into a short-term Hold rating.